Eversept Partners’s Amicus Therapeutics FOLD Stock Holding History

Eversept Partners’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-478,245	Closed	-$5.14M	–	79
2022 Q2	$5.14M	Buy	+478,245	New	+$3.94M	0.37%	48
2019 Q1	–	Sell	-62,750	Closed	-$601K	–	55
2018 Q4	$601K	Sell	62,750 -17,000	-21%	-$187K	0.33%	41
2018 Q3	$964K	Buy	+79,750	New	+$1.12M	0.42%	36

Other funds holding FOLD

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Eversept Partners's FOLD Position: Q3 2022 in Review

Eversept Partners sold out of Amicus Therapeutics (FOLD) in Q3 2022, closing a stake of 478,245 shares — an estimated $5.14M sold.

Eversept Partners first reported a position in FOLD in Q3 2018 and held it in 3 quarters. The position peaked at $5.14M in Q2 2022. 222 funds tracked by Wall St. Rank hold FOLD as of Q3 2022.

Eversept Partners reported no remaining Amicus Therapeutics position as of Q3 2022 after selling out during the quarter.
Eversept Partners sold 478,245 Amicus Therapeutics shares in Q3 2022, an estimated $5.14M.
Eversept Partners first reported a position in Amicus Therapeutics in Q3 2018 and held it in 3 quarters.
Eversept Partners's Amicus Therapeutics position peaked at $5.14M in Q2 2022.
222 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q3 2022.

Based on Eversept Partners's 13F filing for Q3 2022, filed 14 Nov 2022.